CFDE Data Portal | Search BMS1P22

	Label	Description
	BMS1P22 Gene (Entity type)	ENSG00000290415 - BMS1 pseudogene 22
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE198930 prunetin AGS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE186709 GSE186711 MLL inhibition 4 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE147815 GSE147817 LSD1 inhibition McCoy 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168401 harmine U2OS 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

BMS1P22

ENSG00000290415 - BMS1 pseudogene 22

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

GSE198930 prunetin AGS 1 v 0 human dn

A Gene Set from LINCS

GSE135514 dasatinib 8 v 9 human up

A Gene Set from LINCS

GSE186709 GSE186711 MLL inhibition 4 v 6 human dn

A Gene Set from LINCS

GSE147815 GSE147817 LSD1 inhibition McCoy 2 v 3 human dn

A Gene Set from LINCS

GSE168401 harmine U2OS 1 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.